PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)				re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
				Application Number	10/765,236	
				Filing Date	1/26/2004	
				First Named Inventor	Matthias Rath	
				Art Unit	1614	
				Examiner Name	Brian Yong S. Kwon	
Sheet	1	of	1	Attorney Docket Number	11957/46503	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	1	KOSTNER, "HMG CoA reductase inhibitor lower LDL cholesterol without reducing Lp(a) levels" Circulation, 1989 Nov, Vol 80 No. 5, pgs 1313-1319	
	2	HEGELE, "The effect of genetic determinants of low density lipoprotein levels on lipoprotein (a)" Clin Invest Med, 1991 April, Vol 14 No. 2, pgs 146-152	
·	3	WATTS, "Liprotein (a) as an independentcommon hypercholesterolaemia" J Clin Pathol, 1993 March, Vol 46 No. 3, pgs 267-270	
	4	OLOFINSKAIA, "Lipoprotein (A) in patients with coronary atherosclerosis" Kardiologiia, 1991 Oct, Vol 31 No. 10, pgs 36-38	
,			
•			
	_		-

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and aubmitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.